Coherus Biosciences appoints Lisa M. Bell senior VP, Global Regulatory Affairs
Coherus Biosciences, a biologics platform company delivering biosimilar therapeutics, has appointed Lisa M. Bell, Ph.D. senior vice president, Global Regulatory Affairs. Bell joins Coherus with more than 15 years of experience in global regulatory affairs and drug development across various therapeutic areas at preeminent biotech companies.
Denny Lanfear, president and CEO of Coherus, said, "Bell’s experience in overseeing global applications to approval and implementing cutting-edge regulatory strategies will be critical as we strive to obtain approved labels for ourselves and our partners."
Bell was global head of Regulatory, Pharmacovigilance, Medical Writing and Development Quality Assurance at BioMarin Pharmaceutical. Previously, she also held leadership roles at Facet Biotech and Genentech. Bell has extensive experience in driving regulatory strategy of large and small molecule programs from preclinical through post-marketing phases of development. She has worked across several therapeutic areas including oncology, neurology/inflammation and rare diseases.